Cardiovascular Systems Inc

Cardiovascular Systems — Q1 FY2020 Earnings Presentation

8 slides from Cardiovascular Systems's earnings presentation, Oct 29, 2019

  1. Slide 1: Q1 FY20 Earnings Call October 29, 2019

    Q1 FY20 Earnings Call October 29, 2019

  2. Slide 2: Safe Harbor: Forward Looking Statements

    Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem

  3. Slide 3: Q1 Worldwide Revenues of $64.5 Million

    Q1 Worldwide Revenues of $64.5 Million 15% Increase in Revenue ($ in millions) Revenues US Coronary grew 17% Drivers US Peripheral grew 10% 10% unit growth 60% of accounts purchased US Drivers procedure support devices Peripheral, US Coronary, 12% unit growth $45.3 Radial and Exchangeable $16.3 OBL

  4. Slide 4: Financial Results

    Q1 FY20 Financial Results ($ in millions) Worldwide Peripheral Revenue Growth Worldwide Coronary Revenue Growth $48.3 $45.5 $20.0 $44.2 $45.2 $19.0 $41.2 $18.2 10% $16.0 26% growth $15.0 growth in Q1 in Q1 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Gross Margin C

  5. Slide 5: Highlights

    Q1 FY20 Highlights Financial Operational - Peripheral Operational – Coronary Other Revenue Growth +15% vs. LY • Strong case support drove • Continued adoption of coronary • Sold ≈21,200 OAS units strength in hospitals and office toolkit featuring OAS with • Certified 79 international Gross Margin 80

  6. Slide 6: Key Events & Milestones

    Key Events & Milestones FY19A FY20E FY21E Sold 80,650 OAS WIRION acquisition • Hemodynamic support - First in Human International revenue = $7.9M LIBERTY 360 3-Year Data • International revenue = $15-$17.5M Launched OAS in SE Asia, Europe • Launch OAS in up to 10 new countries • Launch OAS in Canada

  7. Slide 7: FY20 Guidance (Reiterated as of 10-29-19)

    FY20 Guidance (Reiterated as of 10-29-19) For fiscal 2020 ending June 30, 2020, CSI anticipates: • Revenue of $278 million to $283 million, representing 12% to 14% growth compared with fiscal 2019; • Gross profit margin of 79% to 80%; • Net income (loss) of approximately breakeven, excluding approxi

  8. Slide 8: Investor Contact

    NASDAQ: CSII Investor Contact: Jack Nielsen 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2019 Cardiovascular Systems, Inc. OrbusNeich®, Teleport® and Sapphire® are tra

Cardiovascular Systems — Q1 FY2020 Earnings Presentation on 6ix